ÂÜÀòÂÒÂ×

Carl Friddle is an experienced leader in the pharmaceutical and biotechnology sectors, currently serving as Field Director for the MSL Rare Disease Team at Apellis Pharmaceuticals since May 2021. Previously, Carl was the Director of the MSL Team at BioCryst Pharmaceuticals, where a new MSL team was established to support a novel compound. Carl's experience extends to roles at Mallinckrodt Pharmaceuticals, where oversight of MSL teams in immune cell therapy and pulmonary critical care was provided, and earlier positions at IKARIA, MDea, and Ipsen focused on various therapeutic areas. Carl's academic background includes a Ph.D. in Genetics from Stanford University School of Medicine and a B.A. in Biochemistry and Biology from Rice University. Additionally, Carl has a strong history of scientific innovation at Lexicon Pharmaceuticals, alongside early career research as a postdoctoral fellow at Lawrence Berkeley National Laboratory.